aureus, a core microbial driver of atopic dermatitis, offering a potential novel avenue for treatment. "We are thrilled to have our first participant enrolled," said Chief Executive Officer Cheri ...

The CDA-AMC recommended that Ebglyss not be reimbursed by public drug plans, excluding Quebec, for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and ...

Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...

The South San Francisco, Calif., biopharmaceutical company in May shut down two trials of zelnecirnon, which was being evaluated as a treatment for asthma and atopic dermatitis.

The following is a summary of “Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today ann ...

Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on November 11.Don't Miss our Black ...